Frank Svec, MD, PhD Clinical Professor of Medicine Tulane University School of Medicine New Orleans, Louisiana Kevan Chambers Announcer Medscape Diabetes.

Slides:



Advertisements
Similar presentations
2011 Guidelines for Field Triage of Injured Patients.
Advertisements

Type 1 Diabetes in Adults Type 1 Diabetes in Adults Francine Ratner Kaufman, M.D. Distinguished Professor of Pediatrics The Keck School of Medicine of.
Michael L. Parchman, MD1 Amer Kassai, PhD2 Jacqueline A. Pugh, MD1
National expertise and capacity building approaches Subgroup on HES, Luxembourg, 20 January 2010.
Sandra G. Adams, MD, MS Pulmonary Diseases / Critical Care Medicine University of Texas Health Science Center at San Antonio South Texas Veterans Healthcare.
County-level Estimates of Diagnosed Diabetes Incidence among Adults aged ≥ 20 years old Trends
The Impact of Diabetes Mellitus in the United States
Age-Adjusted Prevalence of Diagnosed Diabetes Among U.S. Adults
CDC’s Division of Diabetes Translation. National Diabetes Surveillance System available at Obesity (BMI≥30 kg/m.
Precepting medical students in ambulatory clinical settings: from barriers to opportunities… Tom Barber, MD Co-director, Ambulatory Internal Medicine Clerkship,
Clinical Alliances and Partnerships Raul A. Romaguera, DMD, MPH Division of HIV/AIDS Prevention Centers for Disease Control and Prevention March 11, 2004.
What Causes Microvascular and Macrovascular Complications in Patients with Type 2 Diabetes? Charles A. Reasner, MD Professor of Medicine University of.
Tracey B. Newhall, MSN, RN, OCN La Salle University School of Nursing and Health Sciences, Philadelphia, PA November 4, 2013 American Public Health Association.
STD Screening in HIV Clinics: Value and Implications Thomas Farley, MD MPH Tulane University Deborah Cohen, MD MPH RAND Corporation.
TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER Libraries of The Health Sciences MSIII’s Internal Medicine Clerkship Point of Care Evidence Based Medicine.
2.11 Conduct Medication Management University Medical Center Health System Lubbock, TX Jason Mills, PharmD, RPh Assistant Director of Pharmacy.
Texas Diabetes Education & Care Management Project Funded by Bristol-Myers Squibb Foundation Bureau of Primary Health, HRSA CDC Diabetes Prevention (in-kind.
® Introduction The Skinny on Obesity in Texas: BMI in Texas Family Medicine Clinics Kristin M. Yeung, Ramin Poursani, MD, Sandra K. Burge, PhD The University.
® Introduction Mental Health Predictors of Pain and Function in Patients with Chronic Low Back Pain Olivia D. Lara, K. Ashok Kumar MD FRCS Sandra Burge,
Turning Data into Action for Colorectal Cancer November 17, 2014 Jessica Shaffer, Director, Maine CDC Colorectal Cancer Control Program
Health Disparities in Cardiovascular Disease Paula A. Johnson, MD, MPH Chief, Division of Women’s Health; Executive Director, Connors Center for Women’s.
Leadership and Management Training for physicians Maria V. Gibson, MD, PhD Trident / MUSC Family Medicine Residency Program Background Practice Problem.
Benton Community Health Center Located at: 530 NW 27 th Street Corvallis, Oregon (inside the Public Services building) Medical Staff consists of: 3 Physicians.
Darren A. DeWalt, MD, MPH Division of General Internal Medicine Maihan B. Vu, Dr.PH, MPH Center for Health Promotion and Disease Prevention University.
Julio A. Ramirez, MD, FACP Professor of Medicine Chief, Infectious Diseases Division, University of Louisville Chief, Infectious Diseases Section, Veterans.
STDs in Adolescents and Young Adults Sexually Transmitted Disease Surveillance 2003 Division of STD Prevention.
The Effect of Quality Improvement on Racial Disparities in Diabetes Care Thomas D. Sequist, MD MPH Alyce S. Adams, PhD Fang Zhang, MS Dennis Ross-Degnan,
® From Bad to Worse: Comorbidities and Chronic Lower Back Pain Margaret Cecere JD, Richard Young MD, Sandra Burge PhD The University of Texas Health Science.
Using HIV Surveillance to Achieve High Impact Prevention Irene Hall, PhD, FACE AIDS 2012 High-Impact Prevention: Reducing the HIV Epidemic in the United.
Lesson One: Why study type 2 diabetes? Today we will…  Learn about different types of diabetes  See the prevalence of type 2 diabetes in the U.S.  Ask.
CDC’s Division of Diabetes Translation. National Diabetes Surveillance System available at Obesity (BMI≥30 kg/m.
Lesson One: Why study type 2 diabetes? Today we will…  Learn about different types of diabetes  See the prevalence of type 2 diabetes in the U.S.  Ask.
Cardiovascular Disease Healthy Kansans 2010 Steering Committee Meeting April 22, 2005.
Fighting Obesity and Inactivity: Role of Parks and Community Siripoom McKay, MD.
Diabetes Update Division of Endocrinology Department of Medicine Wayne State University Medical School Detroit, Michigan Part 1 of 3.
STDs in Adolescents and Young Adults Sexually Transmitted Disease Surveillance 1998 Division of STD Prevention.
Incorporating Multiple Evidence Sources for the Assessment of Breast Cancer Policies and Practices J. Jackson-Thompson, Gentry White, Missouri Cancer Registry,
STDs in Adolescents and Young Adults Sexually Transmitted Disease Surveillance 2007 Division of STD Prevention.
1 Reducing Health Disparities Among Hispanic Elders: Lessons from a Learning Network Team San Antonio AHRQ Annual Meeting 2008 September 10, 2008 Washington,
Part 1 of 4. Program Editors Ralph Anthony DeFronzo, MD Professor of Medicine and Chief of the Diabetes Division University of Texas Health Science Center.
STDs in Adolescents and Young Adults Sexually Transmitted Disease Surveillance 1999 Division of STD Prevention.
Chlamydia: Reported Cases, Rates, and Screening in Midwest States Tandra R. Gordon, M.S., 1 Brian C. Gordon, PhD, 2 and Lori W. Turner, PhD 2 Southern.
STD’s in Adolescents and Young Adults Sexually Transmitted Disease Surveillance 2001 Division of STD Prevention.
® UTHSCSA Experience (I): SPs for Baseline Assessment We incorporated SP scenarios in our Objective Structured Clinical Evaluation (OSCE), which is administered.
Oral Health and Diabetes: A Two Way Street Maria Emanuel Ryan D.D.S., Ph.D. Professor of Oral Biology and Pathology Associate Dean of Strategic Planning.
Importance of HIV Education of HIV Screening and Risk Among Adults 65 Years Old and Older In A Senior Center JESSICA WARD RN,BSN,FNP COPPIN STATE UNIVERSITY.
Promoting Patient Involvement in Medication Decisions David H. Hickam, MD, MPH Professor, Dept. of Medicine Oregon Health & Science University Portland,
STDs in Adolescents and Young Adults Sexually Transmitted Disease Surveillance 2004 Division of STD Prevention.
Regional Genetics Service Collaboratives; setting the context for analyzing the impact Sara Copeland, MD Chief, Genetics Services Branch September 11,
Improving Community Health through Planning and Partnerships Albemarle and Charlottesville Community Health Council.
Copyright © 2008 Delmar. All rights reserved. Chapter 4 Epidemiology and Public Health Nursing.
CDC’s Division of Diabetes Translation. United States Diabetes Surveillance System available at Obesity (BMI≥30 kg/m 2.
Report Back: 21st International AIDS Conference (Durban, South Africa)
2012 ADA Clinical Practice Guidelines Therapies for DM- Type 2
The Texas A&M KSTAR Fitness for Duty Evaluation,1.0
Bonnie T. Jortberg, MS, RD, CDE David Gaspar, MD
Learn about different types of diabetes
Dorothy Trevino, Ph.D. Catalina Triana, M.D.
Department of Emergency Medicine Kevin Biese, MD, MAT
Patient-Centered Clinical Method
Cardiovascular Disease (CVD) in Texas
Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with.
LSU Health Sciences Center – New Orleans Department of Microbiology, Immunology and Parasitology SPRING 2009 SEMINAR SERIES “Understanding the Mechanisms.
Kaplan-Meier plot of incident CVD according to the treatment group over a 4-year period following intensification of diabetes therapy. Kaplan-Meier plot.
1994 Methodology The percent of U.S. adults who are obese or who have diagnosed diabetes was determined by using data from the Behavioral Risk Factor Surveillance.
Source: CDC, National Diabetes Statistics Report, 2014
Patient-Centered Clinical Method
Trends in age-adjusted diagnosed diabetes prevalence and incidence among adults aged 18–79 years, 1980–2017. Trends in age-adjusted diagnosed diabetes.
Age-standardized* prevalence and number of cases of diagnosed diabetes among individuals aged 1 year and older, Canada, 1998/99 to 2008/09. *Age-standardized.
Presentation transcript:

Frank Svec, MD, PhD Clinical Professor of Medicine Tulane University School of Medicine New Orleans, Louisiana Kevan Chambers Announcer Medscape Diabetes & Endocrinology Challenges in the Management of T2DM—Exploring the Role of GLP-1 Receptor Agonists: Southern Region

During today’s discussion, we will present 2 interactive questions You may also submit a question at any time during the program by using the “Ask a Question” box in the lower right- hand corner of your screen We hope to be able to answer at least some of your questions at the end of the program There will be a brief assessment at the end of the program asking about the changes that you might make in your practice, on the basis of your participation today. Your responses will help us to improve the content of this and future educational programs

Frank Svec, MD, PhD Clinical Professor of Medicine Tulane University School of Medicine New Orleans, Louisiana

Ralph A. DeFronzo, MD Professor of Medicine Chief of Diabetes Division University of Texas Health Science Center at San Antonio San Antonio, Texas Staff Physician Department of Medicine Audie L. Murphy Division South Texas Veterans Health Care System San Antonio, Texas

Program Goal Review the incidence and prevalence of type 2 diabetes mellitus (T2DM) Evaluate evidence-based guidelines for the management of diabetes Focus on the role of glucagon-like peptide (GLP)-1 receptor agonists to help you tailor therapies to your patients with T2DM

Age-Adjusted Percentage of US Adults With Diagnosed Diabetes Centers for Disease Control and Prevention: National Diabetes Surveillance System Missing Data <4.5% % % % ≥9.0%

a Centers for Disease Control and Prevention b National Institute of Diabetes and Digestive and Kidney Diseases Incidence of T2DM Approximately 20 million individuals with T2DM in the United States a Additional 4-5 million individuals with undiagnosed diabetes a 60 million individuals with prediabetes (ie, impaired glucose tolerance, impaired fasting glucose) b

Obesity Trends* Among US Adults *BMI ≥ 30 kg/m 2, or about 30 lb overweight for 5’4” person. Centers for Disease Control and Prevention No Data <10% 10–14%15–19% 20–24%25–29%≥30%

In your region, what percentage of your patients are obese? A. ≤ 25% B. 26%-50% C. 51%-75% D. ≥ 76%

Initial Presentation 49-year-old man with a 1-year history of T2DM Waiter in the French Quarter; 2 meals/day; weight conscious Father died of coronary disease; older brother has coronary disease Initial glycated hemoglobin (A1c) 9.1%; BMI = 29.5 kg/m 2 Case 1 A1c today 8.1%; BMI = 28.8 kg/m 2 ; LDL = 87 mg/dL; HDL = 33 mg/dL Metformin 1000 mg twice daily and statin Is concerned about heart disease; wants to lose weight; nervous about insulin

Case Presentations, Continued Cannot exercise 2 meals/day; snacks; drinks on the weekend Does not check blood glucose values at home BMI = 33.2 kg/m 2 ; A1c 7.9%; LDL = 138 mg/dL; SCr = 1.6 mg/dL; blood pressure = 137/88 mm Hg ACE inhibitor/thiazide, sulfonylurea Case 2 67-year-old woman with a long history of T2DM Cared for at Charity Hospital before Hurricane Katrina; moved to Mississippi; back to New Orleans Old medical records lost On insulin? Lumbar disk disease and hypertension

Polling Question #1 Results

Rodgers G. T2DM Epidemic and Complications 4000 new cases of diabetes are diagnosed daily 800 deaths from individuals with T2DM daily 200 individuals with T2DM experience an amputation daily 50 individuals with T2DM develop blindness daily

a Lee ET, et al. Diabetes Care. 2002;25: b CDC. MMWR Morb Mortal Wkly Rep. 2004;53: c AHRQ. Ethnic Disparities Highest incidence of diabetes among American Indians a High incidence of diabetes among Hispanics, Mexican Americans, and African Americans b,c Lowest incidence of diabetes among whites

a Lotufo PA, et al. Arch Intern Med. 2001;161: b National Institute of Diabetes and Digestive and Kidney Diseases Diabetes and Cardiovascular Disease Increased incidence of atherosclerotic cardiovascular complications a Incidence of myocardial infarction and stroke increased a High cost of managing micro- and macrovascular complications b

Challenges to Diabetes Care Complications among undiagnosed individuals with diabetes Cost of medication Patient propensity to lose weight

What is your greatest obstacle to initiating therapy with GLP-1 receptor agonists? A. Not being up-to-date on current safety and efficacy evidence supporting use of these agents in T2DM B. Cost of medication/insurance/managed care issues C. They offer no advantages over current antidiabetic agents D. Unfamiliarity with placement of this class within treatment guidelines E. Patients’ fear of injections or other patient-related factors

Next Steps Reinforce positive results; his BMI went down Continue to reinforce the importance of diet and exercise GLP-1 agonist should be considered, given that his A1c is not at goal on metformin; he is worried about his heart, and wants to lose weight Need to check serum creatinine level and liver function Ask about history of pancreatitis Case 1 49-year-old man with 1-year history of T2DM; on metformin; A1c, 8.1%; scared of insulin, worried about heart disease, and wants to lose more weight

Exenatide Sustained A1c Reductions Over 82 Weeks 82-wk completer, N = 314; 82-wk ITT, N = 551; Mean ±SE. Time (week) Placebo-controlled Open-label extension Change in A1c (%) (All patients 10 mg BID) 8.3% 8.4% Mean Baseline A1c 82-Week ITT 82-Week Completer Blonde L, et al. Diabetes Obes Metab. 2006;8:

Durability of Exenatide: Weight

Effects of GLP-1 Agonists on Cardiovascular Risk Factors A subset achieved 3.5 years of exenatide exposure and had serum lipids available for analysis (n = 151) Triglycerides decreased 12% (P =.0003) Total cholesterol decreased 5% (P =.0007) LDL-C decreased 6% (P <.0001) HDL-C increased 24% (P <.0001) Klonoff DC, et al. Curr Med Res Opin. 2008;24:

Follow-up Warn him about the potential gastrointestinal side effects of GLP-1 agonists (nausea, vomiting) and that they generally abate over time Educate on the need to control glucose and weight Review cardiovascular risk parameters Test blood glucose twice daily – before breakfast, before dinner DPP-4 inhibitors are a possibility, but they offer modest glucose lowering and are weight neutral Case 1

Diabetes Algorithms and A1c Goal A1c Goal American Diabetes Association ≤ 7% American Association of Clinical Endocrinologists ≤ 6.5% European Association for the Study of Diabetes ≤ 6.5% Emerging Evidence/Expert Opinion ≤ 6%

American Diabetes Association American Diabetes Association. Diabetes Care. 2009;32(suppl1):S13-S61. Nathan DM, et al. Diabetes Care. 2006;29: Lowering A1c to below or around 7% has been shown to reduce microvascular and macrovascular complications of T2DM

Lifestyle + MET + PIO + SFU STEP 1 At diagnosis: Lifestyle + MET STEP 2 STEP 3 Lifestyle + MET + Intensive Insulin OR If A1c ≥7% MET = metformin; PIO = pioglitazone; SFU = sulfonylurea *Validation based on clinical trials and clinical judgment Adapted from: Nathan DM, et al. Diabetes Care. 2009;32: Lifestyle + MET + Basal Insulin Lifestyle + MET + SFU Lifestyle + MET + Basal Insulin Tier 2: Less-well-validated therapies* Lifestyle + MET + PIO Lifestyle + MET + GLP-1 Agonist American Diabetes Association/European Association for the Study of Diabetes Tier 1: Well-validated core therapies*

American Association of Clinical Endocrinologists/American College of Endocrinology Rodbard HW, et al. Endocr Pract. 2009;15:

Increased Hepatic Glucose Production Impaired Insulin Secretion Hyperglycemia Decreased Glucose Uptake TZDs GLP-1 analogues DPP-4 inhibitors Sulfonylureas Thiazolidinediones Metformin  Metformin Thiazolidinediones _  Pathophysiologic Approach to Treatment of T2DM DeFronzo RA. Diabetes. 2009;58:

Nathan DM, et al. Diabetes Care. 2006;29: Nathan DM, et al. Diabetes Care. 2009;32: Consensus Statements for T2DM Consensus group of leading international endocrinologists and diabetologists with extensive clinical experience Recent medical literature and all currently approved classes of medications should be considered Common goal is to improve glucose control through individualization of therapy

Polling Question #2 Results

Schnabel CA, et al. Vasc Health Risk Manag. 2006;2: GLP-1 Receptor Agonists First-in-class exenatide approved in 2005 Augment insulin secretion Inhibit glucagon secretion Lower fasting glucose and improve postprandial glucose profile

Insulin secretion β-cell neogenesis β-cell apoptosis Glucagon secretion Glucose production Heart GI Tract Liver Muscle Drucker DJ. Cell Metab. 2006;3: Brain Appetite Cardioprotection Cardiac output Stomach Gastric emptying Neuroprotection Glucose Uptake _ + Stomach GLP-1 GLP-1 Actions in Peripheral Tissue

Side Effects: GLP-1 Receptor Agonists and DPP-4 Inhibitors GLP-1 Receptor AgonistsDPP-4 Inhibitors Side effects GastrointestinalWell tolerated Weight > 85% patients lose weight Weight neutral Administration Twice-daily injection Oral, once daily Other cardiac risk factors ↓ Triglycerides ↑ HDL ↓ Blood pressure Unknown Davidson JA. Cleve Clin J Med. 2009;76(suppl5):S28-S38.

MetforminThiazolidinediones Side effects Gastrointestinal Fluid retention, congestive heart failure, bone fractures Weight Weight neutral Weight gain Renal impairment Restricted > 1.4 mg/dL Seufert J, et al. Clin Ther. 2004;26: Side Effects: Metformin and Thiazolidinediones

Next Steps Case 2 67-year-old woman with a long history of T2DM; babysits grandchildren; on sulfonylurea; A1c, 7.9% Emphasize the importance of exercise and diet Serum creatinine is high, so cannot use metformin Insulin is a common next step and may be considered, but associated with weight gain and hypoglycemia GLP-1 agonists should be considered to help lower glucose levels and may be associated with mild improvements in blood pressure and lipid profile

Exenatide vs Insulin Glargine as Add-on Therapy in T2DM A1c Level (%) * * * * * * Change in Body Weight (kg) Heine RJ, et al. Ann Intern Med. 2005;143: Exenatide group (n = 275) Insulin glargine group (n = 260)

Mean (SE): *P <.005 SFU b MET + SFU c MET a * Change in A1c (%) Baseline n * * -0.5* * * * Placebo BID Exenatide 5 μg BID Exenatide 10 μg BID MET = metformin; SFU = sulfonylurea a DeFronzo R, et al. Diabetes Care. 2005;28: b Buse JB, et al. Diabetes Care. 2004;27: c Kendall D, et al. Diabetes Care. 2005;28: Change in A1c Seen With Exenatide in Phase 3 Clinical Trials

Buse JB, et al. Diabetes Care. 2004;27: Effects of Exenatide in Sulfonylurea- Treated Patients: Weight

Follow-up Illustrate the effects of binge alcohol consumption (hypoglycemia, pancreatitis risk) Another agent may help control hypertension A statin may help lower LDL Encourage home blood glucose monitoring DPP-4 inhibitors can be considered, but insulin may cause unwanted weight gain Case 2

Questions & Answers

Medullary Thyroid Cancer and Pancreatitis Liraglutide-induced medullary carcinoma is rare, but need to evaluate the patient’s risk Increase in incidence of pancreatitis in patients with T2DM, but unclear whether it is associated with use of exenatide Parks M, et al. N Engl J Med. 2010;362:

Differences in Glycemic Control Genetic variation on response to treatment commonly seen Further studies are needed

Challenges in the Management of T2DM—Exploring the Role of GLP-1 Receptor Agonists: Southern Region

Concluding Remarks Treatment of diabetes requires consideration of multiple risk factors Obesity/overweight is a prime factor in the development diabetes Glucose control is important and can be accomplished without worsening adiposity Discussion of side-effect profile of any medication ahead of time will enhance patient acceptance

Summary: T2DM Is 2 Diseases Microvascular complications Macrovascular complications Two distinct pathogenic sequences Two distinct clinical presentations

Thank you for participating in this Regional CME activity. Please take a few moments to read the brief assessment to help us assess the effectiveness of this medical education activity.

Thank you for participating in this Regional CME activity. To proceed to the online CME test, click on the Earn CME Credit link on this page.